##### Table of Contents



U.S. SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM 10-QSB/A
 QUARTERLY REPORT FOR THE QUARTERLY PERIOD
ENDED JUNE 30, 2007
 COMMISSION FILE NO. 0-28077
 GENELINK, INC.
 
 PENNSYLVANIA
    
    23-2795613(State or other jurisdiction of
    
    (I.R.S. Employer Identification No.)incorporation or organization)Newport Financial Center123 Town Square Place, #313Jersey City, New Jersey
    
    07310(Address of principal executive offices)
    
    (Zip Code)
  þ o
  Number of Shares of Common Stock
Outstanding on August 1, 2007
    
    45,094,183
 o þ




---



##### 



EXPLANATORY NOTE
    PagePART I. FINANCIAL INFORMATIONITEM 1 Financial Statements.Consolidated Balance Sheets at June 30, 2007 (unaudited) and December 31, 2006
    
    
    3Consolidated Statements of Income for the three months and six months ended June 30, 2007 and 2006 (unaudited)
    
    
    4Consolidated Statements of Cash Flows for the six months ended June 30, 2007 and 2006 (unaudited)
    
    
    5-6Notes to Interim Consolidated Financial Statements
    
    
    7-9Certification of Chief Executive Officer and Chief Financial OfficerCertification pursuant to 18 U.S.C. Section 1350
  2




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
 
 CONSOLIDATED BALANCE SHEETS
 (Unaudited)June 30, 2007
    
    December 31, 2006ASSETSCash and cash equivalents
    
    $
    42,657
    
    
    $
    149,695Accounts receivable
    
    
    31,191
    
    
    
    32,185Inventory
    
    
    4,281
    
    
    
    5,772Prepaid expenses
    
    
    11,273
    
    
    
    14,421Total current assets
    
    
    89,402
    
    
    
    202,073Property and equipment
    
    
    119,005
    
    
    
    131,645Other assets
    
    
    379,046
    
    
    
    380,675Total assets
    
    $
    587,453
    
    
    $
    714,393LIABILITIESAccounts payable and accrued expenses
    
    $
    396,681
    
    
    $
    365,590Deferred revenue
    
    
    6,666
    
    
    
    15,481Loans payable to officers
    
    
    18,000
    
    
    
    18,000Total current liabilities
    
    
    421,347
    
    
    
    399,071Convertible secured promissory notes payable
    
    
    853,812
    
    
    
    622,890Accrued compensation
    
    
    774,631
    
    
    
    710,323Total liabilities
    
    
    2,049,790
    
    
    
    1,732,284SHAREHOLDERS EQUITY (DEFICIENCY)Common stock, $.01 par value, 125,000,000 and 75,000,000
shares authorized as of June 30, 2007 and December 31,
2006, respectively, 44,917,863 and 41,738,988 shares
issued, 44,511,694 and 41,332,814 outstanding as of June
30, 2007 and December 31, 2006, respectively
    
    
    449,179
    
    
    
    417,390Additional paid in capital
    
    
    7,082,355
    
    
    
    6,982,849Stock warrants
    
    
    3,020,259
    
    
    
    3,011,009Accumulated deficit
    
    
    (11,699,075
    )
    
    
    (11,114,084
    )Treasury stock, 406,169 shares as of June 30, 2007 and
December 31, 2006, at cost
    
    
    (315,055
    )
    
    
    (315,055
    )Total shareholders equity (deficiency)
    
    
    (1,462,337
    )
    
    
    (1,017,891
    )Total liabilities and shareholders
equity (deficiency)
    
    $
    587,453
    
    
    $
    714,393
 The accompanying notes are an integral part of the consolidated financial statements
 3




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
 
 CONSOLIDATED STATEMENTS OF OPERATIONS
 (UNAUDITED)
 For The
    
    For The
    
    For The
    
    For TheThree Months
    
    Three Months
    
    Six Months
    
    Six MonthsEnded
    
    Ended
    
    Ended
    
    EndedJune 30, 2007
    
    June 30, 2006
    
    June 30, 2007
    
    June 30, 2006REVENUE
    
    $
    27,682
    
    
    $
    35,642
    
    
    $
    59,067
    
    
    $
    83,337COST OF GOODS SOLD
    
    
    20,747
    
    
    
    21,086
    
    
    
    45,870
    
    
    
    27,728GROSS PROFIT
    
    
    6,935
    
    
    
    14,556
    
    
    
    13,197
    
    
    
    55,609EXPENSESSelling, general and administrative
    
    
    124,090
    
    
    
    151,652
    
    
    
    275,975
    
    
    
    258,664Consulting
    
    
    36,000
    
    
    
    44,730
    
    
    
    67,648
    
    
    
    90,810Professional fees
    
    
    57,205
    
    
    
    54,904
    
    
    
    221,320
    
    
    
    141,092Advertising and promotion
    
    
    662
    
    
    
    6,245
    
    
    
    4,896
    
    
    
    8,494Amortization and depreciation
    
    
    14,174
    
    
    
    12,963
    
    
    
    28,348
    
    
    
    25,815232,131
    
    
    
    270,494
    
    
    
    598,187
    
    
    
    524,875NET LOSS BEFORE PROVISION FOR
INCOME TAXES
    
    
    (225,196
    )
    
    
    (255,938
    )
    
    
    (584,990
    )
    
    
    (469,266
    )PROVISIONS FOR INCOME TAXES
    
    
    0
    
    
    
    0
    
    
    
    0
    
    
    
    0NET LOSS
    
    $
    (225,196
    )
    
    $
    (255,938
    )
    
    $
    (584,990
    )
    
    $
    (469,266
    )NET LOSS PER SHARE, BASIC AND DILUTED
    
    $
    (0.01
    )
    
    $
    (0.01
    )
    
    $
    (0.01
    )
    
    $
    (0.01
    )Weighted average common shares and diluted
potential common shares
    
    
    44,703,974
    
    
    
    38,640,897
    
    
    
    42,998,189
    
    
    
    37,265,156
 The accompanying notes are an integral part of the consolidated financial statements
 4




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
 
 CONSOLIDATED STATEMENTS OF CASH FLOWS
 (UNAUDITED)
 Six months ended June 30
    
    2007
    
    2006CASH FLOWS FROM OPERATING ACTIVITIESNet loss
    
    $
    (584,990
    )
    
    $
    (469,266
    )Adjustments to reconcile net loss
to net cash used by operating activitiesDepreciation and amortization
    
    
    28,348
    
    
    
    25,815Amortization of discounts on loans payable
    
    
    40,478
    
    
    
    27,432Common stock issued for services
    
    
    0
    
    
    
    24,326Changes in operating assets and liabilitiesAccounts receivable
    
    
    994
    
    
    
    (4,918
    )Inventory
    
    
    1,491
    
    
    
    (4,361
    )Prepaid expenses
    
    
    3,148
    
    
    
    13,810Other assets
    
    
    0
    
    
    
    (5,000
    )Accounts payable and accrued expenses
    
    
    40,644
    
    
    
    (47,351
    )Deferred Revenue
    
    
    (8,815
    )
    
    
    37,699Accrued payroll taxes
    
    
    0
    
    
    
    (7,454
    )Accrued compensation
    
    
    64,308
    
    
    
    58,462Net cash used by operating activities
    
    
    (414,394
    )
    
    
    (350,806
    )CASH FLOWS FROM INVESTING ACTIVITIESCapital expenditures
    
    
    (6,025
    )
    
    
    (12,799
    )Patent acquisition costs
    
    
    (19,494
    )
    
    
    (15,599
    )Net cash used by investing activities
    
    
    (25,519
    )
    
    
    (28,398
    )CASH FLOWS FROM FINANCING ACTIVITIESProceeds from loans and notes payable
    
    
    332,875
    
    
    
    358,541Repayment of loan and notes payable
    
    
    0
    
    
    
    (17,861
    )Proceeds relating to issuance of common stock (net)
    
    
    0
    
    
    
    105,158Net cash provided by financing activities
    
    
    332,875
    
    
    
    445,838
 The accompanying notes are an integral part of the consolidated financial statements
 5




---



##### Table of Contents



GENELINK, INC. AND SUBSIDIARY
 CONSOLIDATED STATEMENTS OF CASH FLOWS
 (UNAUDITED)
 Six months ended June 30
    
    2006
    
    2005NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    
    
    (107,038
    )
    
    
    66,634Cash and cash equivalents, beginning of period
    
    
    149,695
    
    
    
    15,275Cash and cash equivalents, end of period
    
    $
    42,657
    
    
    $
    81,909SUPPLEMENTAL CASH FLOW INFORMATIONCash paid for interest
    
    $
    0
    
    
    $
    941Non-cash financing transactions:Common stock issued for services
    
    $
    0
    
    
    $
    24,326Common stock and stock warrants granted for fundraising
    
    $
    12,938
    
    
    $
    44,100Conversion
of bridge loan and accrued interest to convertible secured loans
    
    $
    0
    
    
    $
    207,891Conversion of notes payable and accrued interest into common stock
    
    $
    121,131
    
    
    $
    0
 The accompanying notes are an integral part of the consolidated financial statements
 6




---



##### Table of Contents



1 
    
    DESCRIPTION OFORGANIZATION
  
 Organization
   ®
 ®
    7




---



##### Table of Contents



2 
    
    BASIS OFPRESENTATION
 
   3 
    
    RELATED PARTYTRANSACTIONS ANDCONVERTIBLESECUREDPROMISSORY NOTES
 
    8




---



##### Table of Contents



4  SUBSEQUENT EVENT
 
    9




---



ITEM 2.
    
    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
   BUSINESS OPERATIONS AND HISTORY
  ®
 ®
  10




---



##### Table of Contents



®
 LIQUIDITY AND CAPITAL RESOURCES
    COMPARISON OF THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2007 TO SIX MONTHS ENDED JUNE 30, 2006
 Financial Condition
   11




---



##### Table of Contents



Current Year Performance and Earnings Outlook
   .
   FACTORS AFFECTING THE COMPANYS BUSINESS AND PROSPECTS
  12




---



##### Table of Contents



ITEM 3. CONTROLS AND PROCEDURES.
 Evaluation of Disclosure Controls and Procedures
   Change In Internal Controls
   Exhibits and Reports on Form 8-K
 (a)
    
    Exhibits
   (b)
    
    Reports on Form 8-K.
 13




---



##### Table of Contents



GENELINK, INC.
(Registrant)Date:  October 15, 2007
    By:
    /s/ Monte E. Taylor, Jr.Monte E. Taylor, Jr.Chief Executive Officer and
Acting Chief  Financial Officer 14